Pletal
Developed to target intermittent claudication, utilized to alleviate symptoms of peripheral vascular disease.
Strengths: 50 · 100mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Cilostazol Tablets
- Therapeutic class
Antiplatelet Agent
- Pharmacological class
Phosphodiesterase-3 Inhibitor
- Contraindications
congestive heart failure; haemostasis disorders; pregnancy
- Precautions and warnings
use with caution in patients with cardiac disease; monitor for bleeding
- Minor side effects
headache; diarrhoea; abnormal stools
- Moderate side effects
tachycardia; palpitations; dizziness
- Dosage forms
Tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Otsuka Pharmaceutical
- Onset Time
2–4 weeks
- Duration
12 hours
- Storage instructions
Store below 30°C.
- Drug interactions
clopidogrel; aspirin; erythromycin; omeprazole
- Age restrictions
Not recommended for children.
- Pregnancy and breastfeeding
Pregnancy: Contraindicated. Breastfeeding: Not recommended.
Serious side effects
ventricular tachycardia — requires immediate medical attention; intracranial haemorrhage — requires immediate medical attention
Patient summary
Developed to target intermittent claudication, utilized to alleviate symptoms of peripheral vascular disease.
Mechanism of action
Cilostazol inhibits phosphodiesterase-3, resulting in increased cAMP levels, which inhibits platelet aggregation and promotes vasodilation.
Pletal
Developed to target intermittent claudication, utilized to alleviate symptoms of peripheral vascular disease.
Editorial Notes
- Active ingredient(s): Cilostazol
- Listed indication(s): Intermittent Claudication
Usually available as
- 120 tablets - 50 mg727-50-mg-3836
- 90 tablets - 100 mg727-100-mg-3841